The COPPER-A Trial: The Occlusion Perfusion Catheter for Optimal Delivery of Paclitaxel for the Prevention of Endovascular Restenosis - Above and Below the Knee
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 112
- 试验地点
- 34
- 主要终点
- Primary Patency
研究概览
简要总结
The purpose of this study is to assess the safety and efficacy of paclitaxel administration using the occlusion perfusion catheter (OPC) for the prevention of restenosis in infrainguinal de novo, restenotic femoropopliteal and infrapopliteal stenoses and occlusions, and in-stent restenosis.
详细描述
The purpose of this study is to assess the safety and efficacy of paclitaxel administration using the occlusion perfusion catheter (OPC) for the prevention of restenosis in infrainguinal de novo, restenotic femoropopliteal and infrapopliteal stenoses and occlusions, and in-stent restenosis. Subjects will be treated with the endovascular intervention selected by the treating physician in SFA reference vessels ranging from 4mm to 7mm in diameter and infrapopliteal vessels ranging from 2mm to 4mm. Following the achievement of optimal interventional results (less than thirty (30) percent residual stenosis without stenting) the OPC will be placed at the interventional treatment area and paclitaxel will be delivered to the treated segment. Data will be collected to assess acute safety, long-term safety and durability to demonstrate the safety and efficacy of paclitaxel delivered with the ACT, Inc. OPC device.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •General Inclusion Criteria:
- •Willing and able to provide informed consent and comply with all study requirements;
- •Candidate for peripheral vascular femoropopliteal or infrapopliteal percutaneous intervention;
- •Must be ≥ 18 years of age;
- •Rutherford category 2, 3, 4, or 5;
- •Willing and able to tolerate dual anti-platelet therapy (DAPT) for a minimum of one (1) month;
- •Lab work within acceptable limits according to standard of care;
- •INR < 2.0 if on warfarin or not on warfarin;
- •Minimum sheath size used for the interventional procedure
- •7x8 OPC Catheter - 7FR.
- •3x15 OPC, 3x15 PRESSANA(TM), or 3x8 PRESSANA(TM) - 6FR.
排除标准
- •Life expectancy < three (3) years;
- •Planned amputation prior to procedure;
- •Pregnancy or nursing (a pregnancy test is required for all women of childbearing capabilities ≤ 7 days prior to the index procedure);
- •Previous intervention of the target lesion with a drug eluting balloon or drug delivery catheter;
- •Any treatment in the target vessel with drug eluting balloon;
- •Acute limb ischemia
- •Known allergy to paclitaxel;
- •Known hypersensitivity to other drugs manufactured in Cremophor® EL (polyoxyethylated castor oil; e.g. Drugs containing polyoxyethylated castor oil are drugs such as miconazole, cyclosporine injection, nelfinavir mesylate, saperconazole, tacrolimus, and xenaderm ointment);
- •Known allergy to anticoagulants;
- •Known TRUE acetylsalicylic acid (ASA) allergy;
- •Use of glycoprotein (GP) IIb/IIIa inhibitors during the procedure visit within 30 days following the index procedure;
- •Target lesion treated with a cryoplasty balloon at the time of the index procedure;
- •Hemorrhagic stroke within six (6) months;
- •Renal failure or chronic kidney disease with GFR ≤30 mL/min or MDRD GFR ≤30 mL/min per 1.73 m2 (or serum creatinine ≥2.5 mg/L within 30 days of index procedure or treated with dialysis);
- •Prior vascular surgery of the index limb;
- •Current enrollment in another investigational device or drug study;
- •After obtaining informed consent, at any point up to introduction of the OPC, the investigator determines the study subject is not appropriate for the study.
- •Angiographic Inclusion Criteria:
- •Reference vessel diameter (RVD) ≥ 4 mm and ≤ 7 mm for femoropopliteal arteries or ≥ 2 mm and ≤ 4 mm for infrapopliteal arteries;
- •Either single or multiple lesions in the SFA and/or popliteal artery or single or multiple lesions in the infrapopliteal arteries (AT, PT, peroneal);
- •For single lesion treatment, minimum lesion length ≥ 20 mm;
- •Minimum of one patent infrapopliteal vessel;
- •Pre-intervention percent DS ≥ 70%.
- •Angiographic Exclusion Criteria:
- •Flow limiting dissection necessitating stent placement prior to OPC use;
- •Post PTA residual stenosis ≥ 30% as visualized by treating physician;
- •Perforation requiring a covered stent;
- •For femoropopliteal target lesion or occlusion location extends distally beyond the P2 region of the popliteal artery or infrapopliteal lesion or occlusion location is at or proximal to the origin of the trifurcation vessel or below the ankle (top of the talus bone);
- •Target lesion within a fractured stent;
- •Target lesion within a stent and restenosed two (2) or more times;
- •Significant (≥ 50% DS) inflow lesion or occlusion left untreated in the ipsilateral Iliac, SFA, or popliteal artery proximal to the target lesion;
- •A lesion treated distal to the target lesion results in compromising inline flow distal to the target lesion;
- •Visible thrombus in the target artery or proximal to the target artery.
结局指标
主要结局
Primary Patency
时间窗: 6 months
Infrapopliteal Lesions: Measured by duplex Doppler ultrasound (DUS) - demonstrated by freedom from target lesion occlusion and clinically free from Target Lesion Revascularization.
Freedom from major adverse events (MAEs)
时间窗: 1 month
MAEs are defined as target limb related death, major amputation in the target limb (amputation above the metatarsals), or target lesion revascularization (TLR) within one (1) month.
次要结局
- Primary Patency(12 months)
- Improvement in Rutherford category(3, 6, and 12 months)
- Primary Assisted Patency(1, 3, 6, and 12 months)
- Secondary Patency(1, 3, 6, and 12 months)
- Freedom from target lesion revascularization (TLR)(1, 3, 6, and 12 months)
- Freedom from target vessel revascularization (TVR)(1, 3, 6, and 12 months)
- Improvement in Walking Impairment Questionnaire scores(6 and 12 months)
- Device Success(Day 1 - Index Procedure)
- Freedom from major adverse events (MAEs)(1, 3, 6, and 12 months)
- Anticipated adverse events(1, 3, 6, and 12 months)